🧬 WIA-BIO-002

Overview

The WIA-BIO-002 standard establishes comprehensive protocols for gene therapy data management, covering viral and non-viral vector design, delivery mechanisms, expression monitoring, and safety surveillance. This standard enables reproducible therapeutic development and regulatory compliance for genetic medicine.

Key Features

Vector Types & Characteristics

Viral Vectors

Non-Viral Vectors

AAV Serotype Selection

Tissue Tropism Guide

Use Cases

Vector Manufacturing & QC

Production Methods

Analytical Assays (Release Criteria)

Clinical Monitoring Protocol

Pre-Treatment Assessments

1. AAV Neutralizing Antibody Screen: ELISA/NAb assay for AAV1-9. Exclusion if titer >1:5 for target serotype
2. Liver Function: Baseline ALT, AST, bilirubin, albumin, INR
3. Immunosuppression Status: Contraindicated in active immunosuppression for some vectors
4. Genetic Confirmation: Bi-allelic mutation confirmation by NGS or Sanger sequencing
5. Baseline Disease Burden: Disease-specific functional assessments

Post-Treatment Surveillance

Integration Site Analysis (Lentiviral/Retroviral)

Methods

# LAM-PCR (Linear Amplification Mediated PCR)
1. Restrict genomic DNA with MseI/Tsp509I
2. Ligate linker cassette to DNA ends
3. Linear amplification with LTR-specific primer
4. Exponential PCR with nested LTR + linker primers
5. NGS sequencing → map to reference genome

# Alternative: Targeted locus amplification (TLA)
- Higher sensitivity for clonal expansions
- Detects integration sites at 0.01% frequency

Clonal Tracking Criteria

Regulatory Pathway

FDA IND (Investigational New Drug) Application

1. Pre-IND Meeting: Discuss CMC, nonclinical, and clinical development plan
2. CMC Section: Vector design, manufacturing process, analytical methods, stability
3. Nonclinical Section: Biodistribution, toxicology (GLP), integration analysis
4. Clinical Protocol: Phase I/II trial design, dose escalation, stopping rules
5. Investigator's Brochure: Comprehensive preclinical and clinical data
6. FDA Response: 30-day review period, clinical hold if deficiencies

BLA (Biologics License Application) for Approval

• Pivotal Trials: Typically 1 or 2 Phase III trials demonstrating efficacy
• RMAT (Regenerative Medicine Advanced Therapy): Expedited designation for qualifying therapies
• Accelerated Approval: Based on surrogate endpoints with post-marketing confirmatory trials
• Priority Review: 6-month review for serious conditions with unmet need

Implementation Example

AAV Vector Design in Code

import { GeneTherapy, AAVVector, DeliveryProtocol } from '@wia/bio-gene-therapy';

// Design AAV9 vector for SMA gene therapy
const vector = new AAVVector({
  serotype: 'AAV9',
  payload: {
    promoter: 'CMV-IE-enhancer/chicken-beta-actin (CB)',
    transgene: 'hSMN1-cDNA',
    polyA: 'SV40-late-polyA',
    totalSize: 4200  // bp (within AAV 4.7kb limit)
  },
  ITRs: 'AAV2-ITR',  // Standard inverted terminal repeats
  packagedGenome: 'single-strand'
});

// Manufacturing parameters
const manufacturing = vector.setManufacturing({
  method: 'triple-transfection',
  cells: 'HEK293',
  purification: ['iodixanol-gradient', 'ion-exchange-chromatography'],
  targetTiter: 1e14,  // vg/mL
  fillVolume: 5.5,    // mL (for 1.1e14 vg/kg at 10kg patient)
});

// Define delivery protocol
const protocol = new DeliveryProtocol({
  route: 'intravenous',
  infusionTime: 60,  // minutes
  premedication: ['prednisolone 1mg/kg'],
  monitoring: {
    vital signs: 'continuous during infusion',
    LFTs: 'weekly x 12 weeks',
    SMN protein: 'monthly x 12 months'
  }
});

// Safety assessments
const safety = {
  biodistribution: await vector.analyzeBiodistribution('mouse', {
    tissues: ['brain', 'spinal-cord', 'liver', 'heart'],
    timepoints: [1, 4, 12, 24] // weeks
  }),
  immunogenicity: await vector.assessImmunogenicity({
    species: 'NHP',
    NAb titers: true,
    T-cell response: true
  })
};

// Generate regulatory submission package
const submission = GeneTherapy.generateIND({
  vector: vector,
  manufacturing: manufacturing,
  nonclinical: safety,
  clinicalProtocol: protocol
});

console.log(submission.summary());